Quick Answer
Orchestra BioMed Holdings, Inc. reported Net Income Loss of -$52.70 million for the year ending 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +13.6% in Net Income Loss from 2024 to 2025.
- This data is from Orchestra BioMed Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Orchestra BioMed Holdings, Inc.'s Net Income Loss has declined by 13,814.3%.
- Historical annual values: Fiscal year 2025: -$52.70 million | Fiscal year 2024: -$61.02 million | Fiscal year 2023: -$49.12 million | Fiscal year 2022: -$33.61 million | Fiscal year 2021: -$378.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: